CA-C3.AI/NCS
17.6.2021 06:02:07 CEST | Business Wire | Press release
C3 AI (NYSE:AI), the Enterprise AI application software company, and NCS, a leading technology services provider and member of the Singtel Group, today announced a strategic partnership focused on delivering enterprise AI solutions to clients in Southeast Asia (SEA) and Australia/New Zealand (ANZ) across multiple industries, including telecommunications, government, financial services, transportation, and more.
This agreement represents C3 AI’s first strategic partnership with a telecommunications group. NCS will leverage its deep domain experience and technology expertise in serving governments and businesses in SEA and ANZ, investing up to S$10 million to develop and deploy enterprise AI applications created on the C3 AI® Suite. C3 AI’s solutions will also be deployed across Singtel, Optus, and other affiliated telecommunications networks to bring the advantages of enterprise AI to their operations and clients.
As the leader in enterprise AI applications, C3 AI’s offerings include the C3 AI Suite, a powerful end-to-end enterprise AI platform; C3 AI Ex Machina, a no-code solution that anyone can use to generate actionable enterprise AI insights; C3 AI CRM, the first enterprise AI-powered CRM solution custom-built for industries; and a comprehensive inventory of pre-built enterprise AI applications. These applications cover a broad range of use cases, such as C3 AI Energy Management for optimizing energy consumption and carbon emissions, C3 AI Predictive Maintenance to reduce unplanned machine downtime, and C3 AI Fraud Detection for financial transactions.
“Our partnership with C3 AI reaffirms NCS’ commitment to build a strong digital partner ecosystem that provides our clients access to world-leading technologies and enterprise solutions,” said NCS CEO Ng Kuo Pin. “We believe that the wave of enterprise-grade AI solutions has arrived and are excited to work with our clients to build the next generation of digital applications with enterprise AI embedded. We look forward to playing our part to unleash the transformative power of enterprise AI across governments and enterprises in Asia-Pacific.”
In its 2021 Global CIO Agenda survey, Gartner found that SEA and ANZ were among the fastest-growing regions in the world to apply digitalization to optimize enterprise processes1 . In addition, CIOs in these regions identified Artificial Intelligence/Machine Learning as a game-changing technology2 . To capitalize on this trend, C3 AI and NCS will establish a Center of Excellence together to jointly explore new solutions that will accelerate the adoption of enterprise AI and develop custom-built offerings tailored to the business requirements of the Asia-Pacific market.
“Our Center of Excellence will bring together experts from C3 AI and NCS to carefully study and respond to the specific needs of organizations and industries in Southeast Asia, Australia, and New Zealand,” said General Manager, Industries and Alliances at C3 AI Gene Reznik. “This will allow us to better serve customers in SEA and ANZ and provide them with the enterprise AI solutions they require to achieve their digital transformation objectives.”
“Singtel and NCS are clear leaders in the deployment and implementation of telecommunication and cloud solutions, and we are incredibly excited to be joining forces with such a respected and forward-looking partner,” said C3 AI Chairman and CEO Thomas M. Siebel. “NCS’ focus on digital transformation will help drive enterprise AI in Asia-Pacific, especially in the telecommunications industry, on a massive scale.”
1 Gartner, '2021 CIO Agenda: Global Perspectives on 'Seize This Opportunity for Digital Business Acceleration', Andy Rowsell-Jones, Tomas Neilsen, Jan-Martin Lowendahl, Chris Howard, Monika Sinha, March 05, 2021
2 Gartner, '2021 CIO Agenda: A Southeast Asia Perspective', Adrian Lee, February 03, 2021; Gartner, '2021 CIO Agenda: An Australia and New Zealand Perspective', Andy Rowsell-Jones, Brian Ferreira, Christopher Bell, December 15, 2021
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is the Enterprise AI application software company that accelerates digital transformation for organizations globally. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai
About NCS
NCS is a member of the Singtel Group and the leading information, communications and technology (ICT) service provider with presence in the Asia Pacific region. NCS delivers end-to-end ICT and digital solutions to help governments and enterprises realise business value through digital transformation and the innovative use of technology. NCS invests in NEXT capabilities of digital, cloud, platform and cyber while continuously strengthening its core offerings of Applications, Infrastructure and Engineering. NCS also believes in building a strong partner eco-system with leading technology players and research institutions to support open innovation and co-creation.
For more information, please visit www.ncs.com.sg .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616006026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom